The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years
Abstract
OBJECTIVE: To evaluate the efficacy and safety of repeated rituximab treatment based on the assessment of peripheral circulating memory B cells over 24 months in patients with relapsing neuromyelitis optica (NMO). DESIGN: Prospective open-label study. SETTING: Institutional referral center for multiple sclerosis. Patients Thirty patients with relapsing NMO or NMO spectrum disorder. Intervention Treatment protocol of rituximab consisted of an induction therapy (375 mg/m² once weekly for 4 weeks or 1000 mg infused twice, with a 2-week interval between the infusions) followed by maintenance therapy. The maintenance therapy was repeated treatment with rituximab (375 mg/m², once) whenever the frequency of reemerging CD27+ memory B cells was more than 0.05% in peripheral blood mononuclear cells by flow cytometric analysis. MAIN OUTCOME MEASURES: Annualized relapse rate, disability (Expanded Disability Status Scale score), anti-aquaporin 4 antibody level, and safety of rituximab treatment. RESULTS: Of 30 patients, 28 showed a marked reduction in relapse rate while taking rituximab over 24 months. The relapse rate was reduced significantly, by 88%, and 70% of patients became relapse-free over 24 months. Disability either improved or stabilized in 97% of patients. Anti-aquaporin 4 antibody levels declined significantly following treatment with rituximab, consistent with the clinical response and the effect on CD27+ memory B cells. Repeated treatment with rituximab was generally well tolerated, and no clinically relevant adverse event leading to discontinuation of treatment was observed. CONCLUSION: Repeated treatment with rituximab appeared to produce consistent and sustained efficacy over 24 months with good tolerability in patients with NMO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,179
The clinical course of neuromyelitis optica (Devic’s syndrome)
Wingerchuk, D. M., Hogancamp, W. F., O’Brien, P. C., & Weinshenker, B. G. (1999) · Neurology · doi:10.1212/wnl.53.5.1107 · Cited by 1,822
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Emery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R. F., Li, N. F., Agarwal, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,060
Carson, K. R., Evens, A. M., Richey, E. A., Habermann, T. M., Focosi, D., Seymour, J. F., Laubach, J., Bawn, S. D., Gordon, L. I., Winter, J. N., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186999 · Cited by 866
An open label study of the effects of rituximab in neuromyelitis optica
Cree, B. A. C., Lamb, S., Morgan, K., Chen, A., Waubant, E., & Genain, C. (2005) · Neurology · doi:10.1212/01.wnl.0000159399.81861.d5 · Cited by 646
Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040119 · Cited by 642
Intrathecal pathogenic anti–aquaporin‐4 antibodies in early neuromyelitis optica
Bennett, J. L., Lam, C., Kalluri, S. R., Saikali, P., Bautista, K., Dupree, C., Glogowska, M., Case, D., Antel, J. P., Owens, G. P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21802 · Cited by 590
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis
Weinshenker, B. G., Wingerchuk, D. M., Vukusic, S., Linbo, L., Pittock, S. J., Lucchinetti, C. F., & Lennon, V. A. (2006) · Annals of Neurology · doi:10.1002/ana.20770 · Cited by 588
Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo
Bradl, M., Misu, T., Takahashi, T., Watanabe, M., Mader, S., Reindl, M., Adzemovic, M., Bauer, J., Berger, T., Fujihara, K., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21837 · Cited by 563
Leandro, M. J., Cambridge, G., Ehrenstein, M. R., & Edwards, J. C. W. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21617 · Cited by 560
Saadoun, S., Waters, P., Bell, B. A., Vincent, A., Verkman, A. S., & Papadopoulos, M. C. (2010) · Brain · doi:10.1093/brain/awp309 · Cited by 548
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial
Bar‐Or, A., Calabresi, P. A. J., Arnold, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E., Gazda, S., Fox, R. J., Panzara, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21363 · Cited by 527
Treatment of Neuromyelitis Optica With Rituximab: Retrospective Analysis of 25 Patients
(2008) · Archives of Neurology · doi:10.1001/archneur.65.11.noc80069 · Cited by 459
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica
Jarius, S., Aboul-Enein, F., Waters, P., Kuenz, B., Hauser, A., Berger, T., Lang, W., Reindl, M., Vincent, A., & Kristoferitsch, W. (2008) · Brain · doi:10.1093/brain/awn240 · Cited by 435
Sfikakis, P. P., Boletis, J., Lionaki, S., Vigklis, V., Fragiadaki, K., Iniotaki, A. G., & Moutsopoulos, H. Μ. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20858 · Cited by 410
NMO-IgG predicts the outcome of recurrent optic neuritis
Matiello, M., Lennon, V. A., Jacob, A., Pittock, S. J., Lucchinetti, C. F., Wingerchuk, D. M., & Weinshenker, B. G. (2008) · Neurology · doi:10.1212/01.wnl.0000303817.82134.da · Cited by 367
Keystone, E., Fleischmann, R., Emery, P., Furst, D. E., van Vollenhoven, R., Bathon, J., Dougados, M., Baldassare, A., Ferraccioli, G., Chubick, A., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23059 · Cited by 337
Dalakas, M. C., Rakocevic, G., Salajegheh, M., Dambrosia, J. M., Hahn, A. F., Raju, R., & McElroy, B. (2009) · Annals of Neurology · doi:10.1002/ana.21577 · Cited by 312
B cells move to centre stage: novel opportunities for autoimmune disease treatment
Browning, J. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2085 · Cited by 279
Cambridge, G., Stohl, W., Leandro, M. J., Migone, T., Hilbert, D. M., & Edwards, J. C. W. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21650 · Cited by 274
Neuromyelitis optica: Passive transfer to rats by human immunoglobulin
Kinoshita, M., Nakatsuji, Y., Kimura, T., Moriya, M., Takata, K., Okuno, T., Kumanogoh, A., Kajiyama, K., Yoshikawa, H., & Sakoda, S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.06.085 · Cited by 249
Human IgM+CD27+ B Cells: Memory B Cells or “Memory” B Cells?
Tangye, S. G., & Good, K. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.1.13 · Cited by 246
Consensus statement on the use of rituximab in patients with rheumatoid arthritis
Smolen, J. S., Keystone, E. C., Emery, P., Breedveld, F. C., Betteridge, N., Burmester, G. R., Dougados, M., Ferraccioli, G., Jaeger, U., Klareskog, L., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.061002 · Cited by 228
Roll, P., Dörner, T., & Tony, H. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23473 · Cited by 187
Rubbert-Roth, A., Tak, P. P., Zerbini, C., Tremblay, J.-L., Carreno, L., Armstrong, G., Collinson, N., Shaw, T. M., & on behalf of the MIRROR Trial Investigators (2010) · Rheumatology · doi:10.1093/rheumatology/keq116 · Cited by 186
Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs
Popa, C., Leandro, M. J., Cambridge, G., & Edwards, J. C. W. (2006) · Rheumatology · doi:10.1093/rheumatology/kel393 · Cited by 164
Vital, E. M. J., Dass, S. J., Rawstron, A. C., Buch, M. H., Goëb, V., Henshaw, K., Ponchel, F., & Emery, P. E. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27359 · Cited by 127
Invited Article: Inhibition of B cell functions
Dalakas, M. C. (2008) · Neurology · doi:10.1212/01.wnl.0000313840.27060.bf · Cited by 119
Long‐Lived Plasma Cells and Their Contribution to Autoimmunity
Hoyer, B. F., Manz, R. A., Radbruch, A., & Hiepe, F. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1313.014 · Cited by 101
Prospects for B-cell-targeted therapy in autoimmune disease
Edwards, J., & Cambridge, G. (2004) · Rheumatology · doi:10.1093/rheumatology/keh446 · Cited by 84
Good and bad memories following rituximab therapy
Clair, E. W. S. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25039 · Cited by 51
Weinstock‐Guttman, B., Miller, C., Yeh, E. A., Stosic, M., Umhauer, M., Batra, N. N. A., Munschauer, F., Zivadinov, R., & Ramanathan, M. K. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508092811 · Cited by 42
Efficacy and Safety of Rituximab in Pediatric Neuromyelitis Optica
Mahmood, N. A., Silver, K. M., Onel, K. B., Ko, M., & Javed, A. (2010) · Journal of Child Neurology · doi:10.1177/0883073810381445 · Cited by 32
Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma
Collins‐Burow, B. M., & Santos, E. S. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.3.257 · Cited by 26
Cited by
Toosy, A. T., Mason, D. F., & Miller, D. H. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70259-x · Cited by 617
Neuromyelitis Optica Study Group (NEMOS), Trebst, C., Jarius, S., Berthele, A., Paul, F., Schippling, S., Wildemann, B., Borisow, N., Kleiter, I., Aktas, O., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-013-7169-7 · Cited by 595
Ramanathan, S., Mohammad, S., Tantsis, E., Nguyen, T. K., Merheb, V., Fung, V. S. C., White, O. B., Broadley, S., Lechner-Scott, J., Vucic, S., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316880 · Cited by 572
Tahara, M., Oeda, T., Okada, K., Kiriyama, T., Ochi, K., Maruyama, H., Fukaura, H., Nomura, K., Shimizu, Y., Mori, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30066-1 · Cited by 378
Neuromyelitis optica: clinical features, immunopathogenesis and treatment
Jarius, S., Wildemann, B., & Paul, F. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12271 · Cited by 342
Metadata
- Authors
- Kim, S.-H.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2011-11-01
- Volume
- 68
- Issue
- 11
- Pages
- 1412
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2130342500
- Cited by
- 295
- References
- 37
- FWCI
- 14.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.